Cours Mabvax Therapeutics Holdings Inc Nasdaq
Actions
US55414P5044
Recherche biotechnologique et médicale
CA 2016 | 148 k 134 k | CA 2017 | - | Capitalisation | 14,41 M 13,06 M |
---|---|---|---|---|---|
Résultat net 2016 | -17 M -15,4 M | Résultat net 2017 | -19 M -17,21 M | VE / CA 2016 | 147 x |
Dette nette 2016 | 470 k 426 k | Dette nette 2017 | 2,48 M 2,25 M | VE / CA 2017 | - |
PER 2016 |
-0,93
x | PER 2017 |
-0,25
x | Employés | - |
Rendement 2016 * |
-
| Rendement 2017 |
-
| Flottant | 92,02% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08/07/14 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08/07/14 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08/07/14 |
Varia. 1 janv. | Capi. | |
---|---|---|
+8,96% | 105 Md | |
-1,43% | 104 Md | |
+4,40% | 22,94 Md | |
-12,15% | 22,34 Md | |
-4,36% | 19,25 Md | |
-39,98% | 17,08 Md | |
-10,04% | 16,96 Md | |
+38,61% | 12,63 Md | |
+313,59% | 8,49 Md |